Ignatiadis, M., Sledge, G. W. & Jeffrey, S. S. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat. Rev. Clin. Oncol. 18, 297–312 (2021).
Zhang, Y. et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N. Engl. J. Med. 381, 1124–1135 (2019).
Lv, J. et al. Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: the EP-SEASON study. Cancer Cell 42, 1401–1414 (2024).
Kurtz, D. M. et al. Dynamic risk profiling using serial tumor biomarkers for personalized outcome prediction. Cell 178, 699–713 (2019).
Lv, J. et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat. Med. 29, 1424–1436 (2023).
Wang, X. Q. et al. Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature 621, 868–876 (2023).
Cohen, S. A., Liu, M. C. & Aleshin, A. Practical recommendations for using ctDNA in clinical decision making. Nature 619, 259–268 (2023).
Nabet, B. Y. et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 183, 363–376 (2020).
Pan, Y. et al. Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients. Cancer Cell 41, 1763–1773 (2023).
Lv, J. et al. Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat. Commun. 10, 3941 (2019).
Lv, J. et al. Improving on-treatment risk stratification of cancer patients with refined response classification and integration of circulating tumor DNA kinetics. BMC Med 20, 268 (2022).
Brierley, J. D. et al. (eds) TNM Classification of Malignant Tumours 8th edn (Wiley-Blackwell, 2016).
Chen, Y. P. et al. Low-dose metronomic chemotherapy improves tumor control in nasopharyngeal carcinoma. Cancer Commun. 42, 909–912 (2022).
Liu, X. et al. Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 403, 2720–2731 (2024).
Liang, Y.-L. et al. Adjuvant PD-1 blockade with camrelizumab for nasopharyngeal carcinoma: the DIPPER randomized clinical trial. J. Am. Med. Assoc. 333, 1589–1598 (2025).
Dong, S. et al. Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 10, 932–940 (2024).
Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N. Engl. J. Med. 386, 2261–2272 (2022).
Tie, J. et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat. Med. 31, 1509–1518 (2025).
Nakamura, Y. et al. ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nat. Med. 30, 3272–3283 (2024).
Tie, J. et al. Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial. Nat. Med. 31, 4291–4300 (2025).
Chen, L. et al. Postoperative human papilloma virus circulating tumor DNA guided adjuvant therapy for human papilloma virus-related oropharyngeal carcinoma (PATH study). Int. J. Radiat. Oncol. Biol. Phys. 124, 676–685 (2026).
Huang, Z. et al. Plasma Epstein–Barr virus DNA temporal clearance pattern during induction-concurrent (chemo)radiation therapy for risk stratification in nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 123, 129–140 (2025).
Chen, Y. P. et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet 398, 303–313 (2021).
Tang, L.-L. et al. CACA guidelines for holistic integrative management of nasopharyngeal carcinoma. Holist. Integr. Oncol. 2, 24, (2023).
Liu, S. L. et al. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 25, 1563–1575 (2024).
Langer, C. J. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17, 1497–1508 (2016).
Rha, S. Y. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 24, 1181–1195 (2023).
Le, Q. T. et al. An international collaboration to harmonize the quantitative plasma Epstein–Barr virus DNA assay for future biomarker-guided trials in nasopharyngeal carcinoma. Clin. Cancer Res. 19, 2208–2215 (2013).
Tang, S. Q. et al. Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. Radiother. Oncol. 167, 179–186 (2022).
Lin, J. C. et al. Quantification of plasma Epstein–Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N. Engl. J. Med. 350, 2461–2470 (2004).
Chan, K. C. A. et al. Analysis of plasma Epstein–Barr virus DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. 377, 513–522 (2017).
Lo, Y. M. et al. Quantitative analysis of cell-free Epstein–Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 59, 1188–1191 (1999).
Schmidt, R. et al. Sample size calculation for the one-sample log-rank test. Stat. Med. 34, 1031–1040 (2015).
Borgan, Ø & Liestøl, K. A note on confidence intervals and bands for the survival function based on transformations. Scand. J. Stat. 17, 35–41 (1990).
Schoenfeld, D. A. Sample-size formula for the proportional-hazards regression model. Biometrics 39, 499–503 (1983).
Kurz, C. F., Krzywinski, M. & Altman, N. Propensity score matching. Nat. Methods 21, 1770–1772 (2024).
Osoba, D., Rodrigues, G., Myles, J., Zee, B. & Pater, J. Interpreting the significance of changes in health-related quality-of-life scores. J. Clin. Oncol. 16, 139–144 (1998).
Bertram, M. Y. et al. Cost-effectiveness thresholds: pros and cons. Bull. World Health Organ. 94, 925–930 (2016).
